151 related articles for article (PubMed ID: 12459378)
1. DMXAA: an antivascular agent with multiple host responses.
Baguley BC; Ching LM
Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1503-11. PubMed ID: 12459378
[TBL] [Abstract][Full Text] [Related]
2. Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice.
Zhao L; Kestell P; Ching LM; Baguley BC
Cancer Chemother Pharmacol; 2002 Jan; 49(1):20-6. PubMed ID: 11855749
[TBL] [Abstract][Full Text] [Related]
3. The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice.
Zhao L; Ching LM; Kestell P; Baguley BC
Br J Cancer; 2002 Aug; 87(4):465-70. PubMed ID: 12177785
[TBL] [Abstract][Full Text] [Related]
4. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice.
Ching LM; Goldsmith D; Joseph WR; Körner H; Sedgwick JD; Baguley BC
Cancer Res; 1999 Jul; 59(14):3304-7. PubMed ID: 10416582
[TBL] [Abstract][Full Text] [Related]
5. NF-kappa B activation in vivo in both host and tumour cells by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Woon ST; Zwain S; Schooltink MA; Newth AL; Baguley BC; Ching LM
Eur J Cancer; 2003 May; 39(8):1176-83. PubMed ID: 12736120
[TBL] [Abstract][Full Text] [Related]
6. Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Zhao L; Kestell P; Philpott M; Ching LM; Zhuang L; Baguley BC
Cancer Chemother Pharmacol; 2001 Jun; 47(6):491-7. PubMed ID: 11459201
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability.
Zhao L; Ching LM; Kestell P; Kelland LR; Baguley BC
Int J Cancer; 2005 Aug; 116(2):322-6. PubMed ID: 15800918
[TBL] [Abstract][Full Text] [Related]
8. Antivascular therapy of cancer: DMXAA.
Baguley BC
Lancet Oncol; 2003 Mar; 4(3):141-8. PubMed ID: 12623359
[TBL] [Abstract][Full Text] [Related]
9. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy.
Joseph WR; Cao Z; Mountjoy KG; Marshall ES; Baguley BC; Ching LM
Cancer Res; 1999 Feb; 59(3):633-8. PubMed ID: 9973211
[TBL] [Abstract][Full Text] [Related]
10. Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents.
Kestell P; Zhao L; Jameson MB; Stratford MR; Folkes LK; Baguley BC
Clin Chim Acta; 2001 Dec; 314(1-2):159-66. PubMed ID: 11718691
[TBL] [Abstract][Full Text] [Related]
11. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM
Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188
[TBL] [Abstract][Full Text] [Related]
12. Effect of 3-fluorothalidomide and 3-methylthalidomide enantiomers on tumor necrosis factor production and antitumor responses to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Chung F; Palmer BD; Muller GW; Man HW; Kestell P; Baguley BC; Ching LM
Oncol Res; 2003; 14(2):75-82. PubMed ID: 14649541
[TBL] [Abstract][Full Text] [Related]
13. Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid.
Browne WL; Wilson WR; Baguley BC; Ching LM
Anticancer Res; 1998; 18(6A):4409-13. PubMed ID: 9891501
[TBL] [Abstract][Full Text] [Related]
14. Antitumour activity of the novel immune modulator 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice lacking the interferon-gamma receptor.
Pang JH; Cao Z; Joseph WR; Baguley BC; Ching LM
Eur J Cancer; 1998 Jul; 34(8):1282-9. PubMed ID: 9849492
[TBL] [Abstract][Full Text] [Related]
15. Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Cao Z; Baguley BC; Ching LM
Cancer Res; 2001 Feb; 61(4):1517-21. PubMed ID: 11245459
[TBL] [Abstract][Full Text] [Related]
16. 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.
Zhou S; Kestell P; Baguley BC; Paxton JW
Invest New Drugs; 2002 Aug; 20(3):281-95. PubMed ID: 12201491
[TBL] [Abstract][Full Text] [Related]
17. Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: relation to vascular effects.
Baguley BC; Zhuang L; Kestell P
Oncol Res; 1997; 9(2):55-60. PubMed ID: 9167186
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid.
Wilson WR; Li AE; Cowan DS; Siim BG
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):905-8. PubMed ID: 9845119
[TBL] [Abstract][Full Text] [Related]
19. Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid.
Cao Z; Joseph WR; Browne WL; Mountjoy KG; Palmer BD; Baguley BC; Ching LM
Br J Cancer; 1999 May; 80(5-6):716-23. PubMed ID: 10360649
[TBL] [Abstract][Full Text] [Related]
20. Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity.
Ching LM; Browne WL; Tchernegovski R; Gregory T; Baguley BC; Palmer BD
Br J Cancer; 1998 Aug; 78(3):336-43. PubMed ID: 9703279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
